Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Treatment of neonatal seizures

INTRODUCTION

The occurrence of neonatal seizures may be the first, and perhaps the only, clinical sign of a central nervous system (CNS) disorder in the newborn infant. Seizures may indicate the presence of a potentially treatable etiology and should prompt an immediate evaluation to determine cause and to institute etiology-specific therapy. In addition, seizures themselves may require emergent therapy, since they can adversely affect the infant's homeostasis or they may contribute to further brain injury. Some types of neonatal seizures are associated with a relatively high incidence of early death and, in survivors, a high incidence of neurologic impairment, developmental delay, and postneonatal epilepsy.

This topic will discuss the approach to treatment of neonatal seizures. The etiology, clinical features and diagnosis of neonatal seizures are discussed separately. (See "Etiology and prognosis of neonatal seizures" and "Neonatal epileptic syndromes" and "Clinical features and electrodiagnosis of neonatal seizures".)

Both seizures and their subsequent therapy may be associated with changes in respiration, heart rate, and blood pressure. An adequate airway and access to the circulatory system must be insured early in the course of treatment.

ETIOLOGIC-SPECIFIC THERAPY

Etiologic specific therapy is critical since it may prevent further brain injury. This is particularly true for seizures associated with some metabolic disorders (eg, hypoglycemia, hypocalcemia, and hypomagnesemia) and with central nervous system (CNS) or systemic infections. Furthermore, neonatal seizures may not be effectively controlled with antiepileptic drugs (AEDs) unless their underlying cause is treated.

The most common etiologies of neonatal seizures are reviewed in the Table (table 1).

                 

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Oct 2014. | This topic last updated: Sep 24, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Wang HS, Kuo MF, Chou ML, et al. Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy. Arch Dis Child 2005; 90:512.
  2. Nicolai J, van Kranen-Mastenbroek VH, Wevers RA, et al. Folinic acid-responsive seizures initially responsive to pyridoxine. Pediatr Neurol 2006; 34:164.
  3. Basura GJ, Hagland SP, Wiltse AM, Gospe SM Jr. Clinical features and the management of pyridoxine-dependent and pyridoxine-responsive seizures: review of 63 North American cases submitted to a patient registry. Eur J Pediatr 2009; 168:697.
  4. Schmitt B, Baumgartner M, Mills PB, et al. Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol 2010; 52:e133.
  5. Bok LA, Halbertsma FJ, Houterman S, et al. Long-term outcome in pyridoxine-dependent epilepsy. Dev Med Child Neurol 2012; 54:849.
  6. Stockler S, Plecko B, Gospe SM Jr, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 2011; 104:48.
  7. Pérez B, Gutiérrez-Solana LG, Verdú A, et al. Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic option. Epilepsia 2013; 54:239.
  8. Proudfoot M, Jardine P, Straukiene A, et al. Long-Term Follow-up of a Successfully Treated Case of Congenital Pyridoxine-Dependent Epilepsy. JIMD Rep 2013; 10:103.
  9. Bok LA, Maurits NM, Willemsen MA, et al. The EEG response to pyridoxine-IV neither identifies nor excludes pyridoxine-dependent epilepsy. Epilepsia 2010; 51:2406.
  10. Segal EB, Grinspan ZM, Mandel AM, Gospe SM Jr. Biomarkers aiding diagnosis of atypical presentation of pyridoxine-dependent epilepsy. Pediatr Neurol 2011; 44:289.
  11. Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006; 12:307.
  12. Mills PB, Footitt EJ, Mills KA, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 2010; 133:2148.
  13. Gallagher RC, Van Hove JL, Scharer G, et al. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol 2009; 65:550.
  14. Glass HC, Wirrell E. Controversies in neonatal seizure management. J Child Neurol 2009; 24:591.
  15. Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med 1999; 341:485.
  16. Pellock JM. Fosphenytoin use in children. Neurology 1996; 46:S14.
  17. Levy, RA, Mattson, RH, Meldrum, BS, Perucca, E (Eds), Antiepileptic Drugs, 4th ed, Raven Press, New York 1995.
  18. DeLorenzo, RJ. Phenytoin. Mechanisms of Action. In: Antiepileptic Drugs, 4th ed, Levy, RH, Mattson, RH, Meldrum, BS (Eds), Raven Press, New York 1995. p.271.
  19. Macdonald, RL. Benzodiazepines. In: Antiepileptic Drugs, 4th ed, Levy, RH, Mattson, RH, Meldrum, BS (Eds), Raven Press, New York 1995. p.695.
  20. Painter, MJ, Gaus, LM. Phenobarbital: Clinical Use. In: Antiepileptic Drugs, 4th ed, Levy, H, Mattson, RH, Meldrum, BS (Eds), Raven Press, New York, 1995. p.401.
  21. Painter MJ, Pippenger C, MacDonald H, Pitlick W. Phenobarbital and diphenylhydantoin levels in neonates with seizures. J Pediatr 1978; 92:315.
  22. Gal P, Toback J, Boer HR, et al. Efficacy of phenobarbital monotherapy in treatment of neonatal seizures -- relationship to blood levels. Neurology 1982; 32:1401.
  23. Donn SM, Grasela TH, Goldstein GW. Safety of a higher loading dose of phenobarbital in the term newborn. Pediatrics 1985; 75:1061.
  24. Bourgeois BF, Dodson WE. Phenytoin elimination in newborns. Neurology 1983; 33:173.
  25. Dodson WE. Antiepileptic drug utilization in pediatric patients. Epilepsia 1984; 25 Suppl 2:S132.
  26. André M, Boutroy MJ, Dubruc C, et al. Clonazepam pharmacokinetics and therapeutic efficacy in neonatal seizures. Eur J Clin Pharmacol 1986; 30:585.
  27. Hellström-Westas L, Westgren U, Rosén I, Svenningsen NW. Lidocaine for treatment of severe seizures in newborn infants. I. Clinical effects and cerebral electrical activity monitoring. Acta Paediatr Scand 1988; 77:79.
  28. Malingré MM, Van Rooij LG, Rademaker CM, et al. Development of an optimal lidocaine infusion strategy for neonatal seizures. Eur J Pediatr 2006; 165:598.
  29. Lundqvist M, Ågren J, Hellström-Westas L, et al. Efficacy and safety of lidocaine for treatment of neonatal seizures. Acta Paediatr 2013; 102:863.
  30. Sheth RD, Buckley DJ, Gutierrez AR, et al. Midazolam in the treatment of refractory neonatal seizures. Clin Neuropharmacol 1996; 19:165.
  31. Castro Conde JR, Hernández Borges AA, Doménech Martínez E, et al. Midazolam in neonatal seizures with no response to phenobarbital. Neurology 2005; 64:876.
  32. Sirsi D, Nangia S, LaMothe J, et al. Successful management of refractory neonatal seizures with midazolam. J Child Neurol 2008; 23:706.
  33. Khan O, Chang E, Cipriani C, et al. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol 2011; 44:265.
  34. Abend NS, Gutierrez-Colina AM, Monk HM, et al. Levetiracetam for treatment of neonatal seizures. J Child Neurol 2011; 26:465.
  35. Khan O, Cipriani C, Wright C, et al. Role of intravenous levetiracetam for acute seizure management in preterm neonates. Pediatr Neurol 2013; 49:340.
  36. Koren G, Butt W, Rajchgot P, et al. Intravenous paraldehyde for seizure control in newborn infants. Neurology 1986; 36:108.
  37. MacKintosh DA, Baird-Lampert J, Buchanan N. Is carbamazepine an alternative maintenance therapy for neonatal seizures? Dev Pharmacol Ther 1987; 10:100.
  38. Sapin JI, Riviello JJ Jr, Grover WD. Efficacy of primidone for seizure control in neonates and young infants. Pediatr Neurol 1988; 4:292.
  39. Gal P, Oles KS, Gilman JT, Weaver R. Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. Neurology 1988; 38:467.
  40. Aicardi J, Mumford JP, Dumas C, Wood S. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia 1996; 37:638.
  41. Barr PA, Buettiker VE, Antony JH. Efficacy of lamotrigine in refractory neonatal seizures. Pediatr Neurol 1999; 20:161.
  42. Silverstein FS, Ferriero DM. Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol 2008; 39:77.
  43. Glass HC, Poulin C, Shevell MI. Topiramate for the treatment of neonatal seizures. Pediatr Neurol 2011; 44:439.
  44. Shoemaker MT, Rotenberg JS. Levetiracetam for the treatment of neonatal seizures. J Child Neurol 2007; 22:95.
  45. Hmaimess G, Kadhim H, Nassogne MC, et al. Levetiracetam in a neonate with malignant migrating partial seizures. Pediatr Neurol 2006; 34:55.
  46. Booth D, Evans DJ. Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev 2004; :CD004218.
  47. Slaughter LA, Patel AD, Slaughter JL. Pharmacological treatment of neonatal seizures: a systematic review. J Child Neurol 2013; 28:351.
  48. Boylan GB, Rennie JM, Chorley G, et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology 2004; 62:486.
  49. Mizrahi EM, Kellaway P. Characterization and classification of neonatal seizures. Neurology 1987; 37:1837.
  50. Mizrahi, EM, Kellaway, P. The response of electroclinical neonatal seizures to antiepileptic drug therapy. Epilepsia 1992; 33:114.
  51. van Rooij LG, Toet MC, van Huffelen AC, et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics 2010; 125:e358.
  52. Boer HR, Gal P. Neonatal seizures: a survey of current practice. Clin Pediatr (Phila) 1982; 21:453.
  53. Fenichel, GM. Paroxysmal disorders. In: Clinical Pediatric Neurology, 3rd ed, WB Saunders, Philadelphia 1997. p.1.